Stacie M.
Stacie M. Alvzrez, Pleasanton, CA US
Patent application number | Description | Published |
---|---|---|
20140367352 | CLOSURE - Described is a closure adapted to be fit on top of containers such as bottles. In various embodiments, the closure may include an outer skirt and an inner skirt. The closure may be engageable with a container neck. In some embodiments, a region of weakness may be adapted to break and/or deform upon an attempt to remove the closure from the container neck. In some embodiments, after the break and/or deformation, the closure may no longer be engageable with the container neck. | 12-18-2014 |
Stacie M. Blaskowski, St. Louis Park, MN US
Patent application number | Description | Published |
---|---|---|
20160114131 | Elongate medical device handle autolock - An embodiment of a handle assembly for an elongate medical device that may reduce the weight and/or expense of traditional handle may include an exterior adjusting knob extending along a longitudinal axis and configured to rotate about the axis, an insert, and a dowel pin. The insert may be configured to engage the adjusting knob and to rotate about the axis responsive to rotation of the adjusting knob. The insert may comprise an annular groove configured to engage a dowel pin, the annular groove comprising a sidewall comprising a chamfer. The dowel pin may be configured to engage the annular groove to resist rotation of the insert. In an embodiment, the insert may comprise plastic or polymer. | 04-28-2016 |
Stacie M. Goldberg, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20150125463 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING - The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. | 05-07-2015 |
20160090417 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING - The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. | 03-31-2016 |